FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer By Ogkologos - April 8, 2026 75 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the findings from the ROSELLA study Source RELATED ARTICLESMORE FROM AUTHOR Low-Dose Pembrolizumab with Dose-Dense Chemotherapy Increases pCR as Neoadjuvant Treatment for Localised TNBC ESMO Advocates for Equal Access to Optimal Cancer Care for all Patients with Cancer at the 79th World Health Assembly Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic Ductal Adenocarcinoma MOST POPULAR Opinion: ‘The UK must be more ambitious than just clearing the... May 24, 2021 ESMO Asia Congress 2024, Singapore, 6-8 December November 27, 2024 FDA Approves Mitomycin Intravesical Solution for Recurrent Low Grade Intermediate Risk... July 31, 2025 Our new strategy to make discoveries, drive progress, and bring hope March 17, 2022 Load more HOT NEWS Studies Test CAR T-Cell Therapies Designed to Overcome Key Limitations Why we need to continue to advocate for global tobacco control Fourth Vaccine Dose Increases in Humoral Immunity Against Omicron Variants in... Uncle Charlie’s Promise
